Yousef Zakharia, MD, of University of Iowa Holden Comprehensive Cancer Center, continues his commentary on the phase Ib/II BTCRC-GU16-043 study investigating guadecitabine and durvalumab in advanced clear cell renal cell carcinoma (RCC). He notes any specific biomarkers that may predict response, as well as where he envisions the potential placement of the combination therapy in the treatment algorithm. ...
Renal Cell Carcinoma
Advertisement
Latest News
Dr. Zakharia explains why guadecitabine plus durvalumab may be a good treatment approach in patients with advanced RCC.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Drs. Braun and Beckermann stress the importance of adopting an integrative approach to biomarker-based research in RCC.
Drs. Braun and Beckermann review JAVELIN Renal 101, focusing on the impact of avelumab and axitinib treatment on RCC.
Drs. Braun and Beckermann discuss the evolving significance of sarcomatoid histology in guiding treatment decisions for RCC.
The ARON-1 study investigated the efficacy of 1L treatment with TKIs versus IO-based combinations in patients with pRCC.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Advertisement
Advertisement
Latest News
Dr. Vandekerkhove explains her research on genomic testing in prostate cancer.
Dr. Zakharia explains why guadecitabine plus durvalumab may be a good treatment approach in patients with advanced RCC.
The benefits of PSA screening alone are offset by excess negative biopsies and the over-detection of low-grade cancers.
